Clinical Trial Update: Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating paricalcitol with zoledronate in relapsed or refractory multiple myeloma and other plasma cell disorders was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Paricalcitol (paricalcitol)
• Zoledronate (zoledronic acid)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | Status: TERMINATED